ClinicalTrials.Veeva

Menu
X

XCancer | Omaha

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Copper Cu 64
64Cu
ACE-232
FPI-2265

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 6 total trials

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer (AMPLIFY)

The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer

Enrolling
Prostate Cancer Patients Who Have Brachytherapy Seed Implant
Prostate Cancer Patients Treated by Radiotherapy
Drug: 64Cu-SAR-bisPSMA

This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfa...

Enrolling
Prostate Adenocarcinoma
Prostate Cancer
Drug: Copper Cu 64 PSMA I&T

This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I\&T). Patient population is adult participants with PSMA positive mCRPC...

Enrolling
Metastatic Castration-resistant Prostate Cancer
Drug: FPI-2265

This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant pros...

Enrolling
mCRPC (Metastatic Castration-resistant Prostate Cancer)
Prostate Cancer (Adenocarcinoma)
Drug: ACE-232 tablets

Trial sponsors

C
C
F
T
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems